Insider Transactions Reported by 25 Insiders of Roivant Sciences Ltd.

Symbol: ROIV on Nasdaq
Location: London

Key facts

ROIV - Roivant Sciences Ltd. has 25 insiders with reported activity on this page.
Net insider value flow over the last year: -$732,401,091.
Recent transaction rows are available for direct filing-level review.

Change

Buy value: $49,957; sell value: $732,451,047.
Net share flow: -34,869,732.

Research use

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$732,401,091.

Buys

$49,957

Shares: 3,315

Insiders: 1

Sells

$732,451,048

Shares: 34,873,047

Insiders: 12

Net

-$732,401,091

Shares: -34,869,732

Insiders: -11

Window (months)	Buy shares	Sell shares	Buy $	Sell $	Net $
0-3	0	1,015,173	$0	$29,575,956	-$29,575,956
3-6	0	19,583,810	$0	$470,537,296	-$470,537,296
6-9	3,315	11,083,561	$49,957	$196,174,250	-$196,124,293
9-12	0	3,190,503	$0	$36,163,546	-$36,163,546

Roivant Sciences Ltd. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Dexcel Pharma Technologies Ltd.	10%+ Owner	$1,064,491,735			Mixed	10 Nov 2022
Vivek Ramaswamy	10%+ Owner	$1,012,161,165	-$149,877,277	-13%	Mixed	11 Dec 2025
SVF Investments (UK) Ltd	10%+ Owner	$755,877,753			Mixed	28 Sep 2023
Sumitomo Chemical Co., Ltd.	10%+ Owner	$737,448,709			Mixed	22 Jun 2023
Matthew Gline	CEO, Director	$488,025,142	-$46,123,053	-8.6%	Filing P/S	16 Apr 2026
Mayukh Sukhatme	President & CIO, Director	$405,304,288	-$38,507,032	-8.7%	Mixed	30 Mar 2026
Daniel Allen Gold	Director	$400,874,218	-$98,028,232	-20%	Filing P/S	11 Feb 2026
Keith S. Manchester	Director	$400,874,218	-$98,028,232	-20%	Filing P/S	11 Feb 2026
QVT Financial LP	Director by Deputization	$400,874,218	-$98,028,232	-20%	Filing P/S	11 Feb 2026
Frank Torti	President and Vant Chair	$294,610,310	-$82,039,460	-22%	Mixed	31 Mar 2026
Eric Venker	President & Immunovant CEO	$171,694,712	-$109,141,120	-39%	Mixed	20 May 2026
VIKING GLOBAL PERFORMANCE LLC	10%+ Owner	$133,352,577			Mixed	22 Jun 2023
VIKING GLOBAL INVESTORS LP	10%+ Owner	$133,352,577			Mixed	22 Jun 2023
Benjamin Zimmer	President, Roivant Health	$12,083,532			Mixed	01 Oct 2021
Richard Pulik	Cfo	$7,715,807	-$9,122,307	-54%	Median	20 May 2026
Ilan Oren	Director	$3,330,343			Median	17 Apr 2026
Jennifer Humes	Chief Accounting Officer	$3,140,182	-$384,073	-11%	Median	20 Apr 2026
James C. Momtazee	Director	$3,030,518			Median	17 Apr 2026
Rakhi Kumar	Chief Accounting Officer	$1,739,920			Mixed	20 Feb 2025
Meghan FitzGerald	Director	$1,179,334	-$1,921,500	-62%	Filing P/S	26 Mar 2026
Andrew Lo	Director	$539,670			Mixed	15 Sep 2022
Melissa B. Epperly	Director	$456,329	-$1,200,573	-72%	Median	17 Apr 2026
Masayo Tada	Director				Mixed	01 Oct 2021
Hiroshi Nomura	Director				Mixed	16 Sep 2022
Patrick Machado	Director				Mixed	01 Oct 2021

Top shareholders of Roivant Sciences Ltd. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FMR LLC	13F 13D/G	Company	10% from 13D/G	77,981,253	$2,160,080,715	—	31 Mar 2026	13F 13D/G
MORGAN STANLEY	13F 13D/G	Company	6.9% from 13D/G	51,828,325	$1,435,644,662	—	31 Mar 2026	13F 13D/G
QVT Financial LP	13F 13D/G 3/4/5	Company · Director by Deputization	4.3% from 13D/G	25,161,237	$696,966,265	—	31 Mar 2026	13F 13D/G 3/4/5
Vivek Ramaswamy	3/4/5 13D/G	10%+ Owner · Ramaswamy Vivek	3.6% from 13D/G	69,161,839 mixed-class rows	$1,012,161,165	-$149,877,277	11 Dec 2025	3/4/5 13D/G
VIKING GLOBAL INVESTORS LP	13D/G 3/4/5 13F	10%+ Owner · Company	3.4%	23,594,831	$356,989,793	-$161,027,803	30 Sep 2025	13D/G 3/4/5 13F
SB INVESTMENT ADVISERS (UK) LTD	13D/G 13F	SB Investment Advisers (UK) Limited · Company	2.3%	16,413,603	$357,488,273	-$520,575,193	31 Dec 2025	13D/G 13F
Mayukh Sukhatme	3/4/5	President & CIO, Director	2.6%	18,677,617	$405,304,288	-$38,507,032	30 Mar 2026	3/4/5
Matthew Gline	3/4/5	CEO, Director	2.3%	16,736,116	$488,025,142	-$46,123,053	16 Apr 2026	3/4/5
BlackRock, Inc.	13F	Company	6.2%	44,254,260	$1,225,842,982	—	31 Mar 2026	13F
UBS Group AG	13F	Company	3.2%	22,619,472	$626,559,375	—	31 Mar 2026	13F
VANGUARD CAPITAL MANAGEMENT LLC	13F	Company	2.9%	20,680,572	$572,851,844	—	31 Mar 2026	13F
VANGUARD PORTFOLIO MANAGEMENT LLC	13F	Company	2.8%	19,838,698	$549,531,935	—	31 Mar 2026	13F
STATE STREET CORP	13F	Company	2.3%	16,186,613	$448,369,180	—	31 Mar 2026	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	1.8%	12,794,097	$354,396,487	—	31 Mar 2026	13F
GOLDMAN SACHS GROUP INC	13F	Company	1.5%	11,111,591	$307,791,071	—	31 Mar 2026	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.4%	10,182,477	$282,113,040	—	31 Mar 2026	13F
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	1.3%	9,675,000	$267,997,500	—	31 Mar 2026	13F
Two Seas Capital LP	13F	Company	1.3%	9,328,291	$258,393,661	—	31 Mar 2026	13F
PERCEPTIVE ADVISORS LLC	13F	Company	1.2%	8,285,461	$229,507,270	—	31 Mar 2026	13F
Patient Square Capital LP	13F	Company	1.1%	8,166,047	$226,199,502	—	31 Mar 2026	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	1%	7,475,866	$207,004,200	—	31 Mar 2026	13F
Assenagon Asset Management S.A.	13F	Company	0.99%	7,076,488	$196,018,718	—	31 Mar 2026	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.98%	6,992,136	$193,683,000	—	31 Mar 2026	13F
Darwin Global Management, Ltd.	13F	Company	0.95%	6,797,300	$179,516,693	—	31 Mar 2026	13F
Invesco Ltd.	13F	Company	0.9%	6,439,145	$178,364,317	—	31 Mar 2026	13F
NATIONAL BANK OF CANADA /FI/	13F	Company	0.88%	6,298,000	$174,454,600	—	31 Mar 2026	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.83%	5,946,858	$161,635,601	—	31 Mar 2026	13F
Rubric Capital Management LP	13F	Company	0.7%	5,000,000	$138,500,000	—	31 Mar 2026	13F
BAKER BROS. ADVISORS LP	13F	Company	0.68%	4,867,723	$134,835,927	—	31 Mar 2026	13F
NORTHERN TRUST CORP	13F	Company	0.49%	3,520,452	$97,516,520	—	31 Mar 2026	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.48%	3,457,448	$95,771,310	—	31 Mar 2026	13F
Qube Research & Technologies Ltd	13F	Company	0.48%	3,450,904	$95,590,041	—	31 Mar 2026	13F
ADAR1 Capital Management, LLC	13F	Company	0.46%	3,285,906	$91,019,596	—	31 Mar 2026	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.44%	3,163,821	$87,637,843	—	31 Mar 2026	13F
JANUS HENDERSON GROUP PLC	13F	Company	0.43%	3,095,448	$85,790,341	—	31 Mar 2026	13F
JENNISON ASSOCIATES LLC	13F	Company	0.42%	2,982,799	$82,623,519	—	31 Mar 2026	13F
VANGUARD FIDUCIARY TRUST CO	13F	Company	0.39%	2,811,121	$77,868,052	—	31 Mar 2026	13F
Affinity Asset Advisors, LLC	13F	Company	0.39%	2,800,000	$77,560,000	—	31 Mar 2026	13F
Bank of New York Mellon Corp	13F	Company	0.38%	2,735,824	$75,782,334	—	31 Mar 2026	13F
Pictet Asset Management Holding SA	13F	Company	0.37%	2,673,233	$74,048,554	—	31 Mar 2026	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.35%	2,516,353	$69,702,978	—	31 Mar 2026	13F
CITADEL ADVISORS LLC	13F	Company	0.35%	2,515,998	$69,693,145	—	31 Mar 2026	13F
BlackBarn Capital Partners LP	13F	Company	0.32%	2,285,117	$63,297,741	—	31 Mar 2026	13F
MARSHALL WACE, LLP	13F	Company	0.31%	2,246,943	$62,240,321	—	31 Mar 2026	13F
DME Capital Management, LP	13F	Company	0.3%	2,152,669	$59,628,931	—	31 Mar 2026	13F
Clearbridge Investments, LLC	13F	Company	0.28%	2,005,565	$55,554,150	—	31 Mar 2026	13F
S.c.a. Candriam	13F	Individual	0.28%	2,001,976	$55,454,735	—	31 Mar 2026	13F
Integral Health Asset Management, LLC	13F	Company	0.28%	2,000,000	$55,400,000	—	31 Mar 2026	13F
Nuveen, LLC	13F	Company	0.27%	1,955,046	$54,154,775	—	31 Mar 2026	13F
Woodline Partners LP	13F	Company	0.24%	1,750,017	$48,475,471	—	31 Mar 2026	13F

Recent Insider Transactions by Companies or Individuals for Roivant Sciences Ltd.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Eric Venker	ROIV	Common Shares	Sale	-11%	$6,054,000	$30.27	-200,000	1,613,063	22 May 2026	Direct
Eric Venker	ROIV	Common Shares	Options Exercise	12.4%			200,000	1,813,063	22 May 2026	Direct
Eric Venker	ROIV	Stock Option (Right to Buy)	Options Exercise	-4.31%			-200,000	4,444,834	22 May 2026	Direct
Eric Venker	ROIV	Common Shares	Tax liability	-2.09%			-34,483	1,613,063	20 May 2026	Direct
Richard Pulik	ROIV	Common Shares	Tax liability	-6.37%			-18,962	278,549	20 May 2026	Direct
Eric Venker	ROIV	Common Shares	Sale	-10.8%	$5,918,000	$29.59	-200,000	1,647,546	20 Apr 2026	Direct
Eric Venker	ROIV	Common Shares	Options Exercise	12.1%			200,000	1,847,546	20 Apr 2026	Direct
Eric Venker	ROIV	Stock Option (Right to Buy)	Options Exercise	-4.13%			-200,000	4,644,834	20 Apr 2026	Direct
Richard Pulik	ROIV	Common Shares	Award	25.6%			60,644	297,511	20 Apr 2026	Direct
Richard Pulik	ROIV	Stock Option (Right to Buy)	Award				84,026	84,026	20 Apr 2026	Direct
Jennifer Humes	ROIV	Common Shares	Award	34.6%			29,173	113,364	20 Apr 2026	Direct
Jennifer Humes	ROIV	Stock Option (Right to Buy)	Award				27,157	27,157	20 Apr 2026	Direct
Ilan Oren	ROIV	Common Shares	Tax liability	-0.08%			-95	120,229	17 Apr 2026	Direct
Ilan Oren	ROIV	Common Shares	Award	0.75%			896	120,324	17 Apr 2026	Direct
Melissa B. Epperly	ROIV	Common Shares	Award	4.24%			670	16,474	17 Apr 2026	Direct
James C. Momtazee	ROIV	Common Shares	Tax liability	-0.09%			-94	109,405	17 Apr 2026	Direct
James C. Momtazee	ROIV	Common Shares	Award	0.43%			469	109,499	17 Apr 2026	Direct
Matthew Gline	ROIV	Common Shares	Sale	-1.7%	$8,449,810	$29.16	-289,774	16,736,116	16 Apr 2026	Direct
Jennifer Humes	ROIV	Common Shares	Sale	-13.8%	$384,073	$28.37	-13,538	84,191	08 Apr 2026	Direct
Frank Torti	ROIV	Common Shares	Tax liability	-1.17%			-160,035	13,576,512	31 Mar 2026	Direct
Matthew Gline	ROIV	Common Shares	Tax liability	-1.76%			-304,684	17,025,890	31 Mar 2026	Direct
Mayukh Sukhatme	ROIV	Common Shares	Tax liability	-0.99%			-187,512	18,677,617	31 Mar 2026	Direct
Matthew Gline	ROIV	Common Shares	Tax liability	-0.31%			-53,826	17,330,574	30 Mar 2026	Direct
Matthew Gline	ROIV	Common Shares	Options Exercise	0.56%			97,319	17,384,400	30 Mar 2026	Direct
Matthew Gline	ROIV	Capped Value Appreciation Rights	Options Exercise	-100%			-2,178,150	0	30 Mar 2026	Direct
Mayukh Sukhatme	ROIV	Common Shares	Tax liability	-0.16%			-29,809	18,865,129	30 Mar 2026	Direct
Mayukh Sukhatme	ROIV	Common Shares	Options Exercise	0.31%			58,391	18,894,938	30 Mar 2026	Direct
Mayukh Sukhatme	ROIV	Capped Value Appreciation Rights	Options Exercise	-100%			-1,306,889	0	30 Mar 2026	Direct
Meghan FitzGerald	ROIV	Common Shares	Sale	-62%	$1,921,500	$27.45	-70,000	42,963	26 Mar 2026	Direct
Meghan FitzGerald	ROIV	Common Shares	Options Exercise	162.9%			70,000	112,963	26 Mar 2026	Direct
Meghan FitzGerald	ROIV	Stock Option (Right to Buy)	Options Exercise	-59%			-70,000	48,578	26 Mar 2026	Direct
Richard Pulik	ROIV	Common Shares	Tax liability	-0.65%			-1,546	236,867	20 Mar 2026	Direct
Jennifer Humes	ROIV	Common Shares	Tax liability	-12.9%			-14,526	97,729	20 Mar 2026	Direct
Eric Venker	ROIV	Common Shares	Sale	-10.8%	$5,648,000	$28.24	-200,000	1,647,546	17 Mar 2026	Direct
Eric Venker	ROIV	Common Shares	Options Exercise	12.1%			200,000	1,847,546	17 Mar 2026	Direct
Eric Venker	ROIV	Stock Option (Right to Buy)	Options Exercise	-3.96%			-200,000	4,844,834	17 Mar 2026	Direct
Melissa B. Epperly	ROIV	Common Shares	Sale	-72.6%	$1,200,573	$28.68	-41,861	15,804	16 Mar 2026	Direct
Frank Torti	ROIV	Common Shares	Sale	-4.1%	$16,159,099	$27.51	-587,390	13,736,547	23 Feb 2026	Direct
Frank Torti	ROIV	Common Shares	Options Exercise	4.28%			587,390	14,323,937	23 Feb 2026	Direct
Frank Torti	ROIV	Stock Option (Right to Buy)	Options Exercise	-16.3%			-587,390	3,026,184	23 Feb 2026	Direct
Richard Pulik	ROIV	Common Shares	Tax liability	-0.42%			-1,000	238,413	20 Feb 2026	Direct
Eric Venker	ROIV	Common Shares	Tax liability	-0.43%			-7,051	1,647,546	20 Feb 2026	Direct
Frank Torti	ROIV	Common Shares	Sale	-6.87%	$27,492,362	$27.15	-1,012,610	13,736,547	20 Feb 2026	Direct
Frank Torti	ROIV	Common Shares	Options Exercise	7.37%			1,012,610	14,749,157	20 Feb 2026	Direct
Frank Torti	ROIV	Stock Option (Right to Buy)	Options Exercise	-21.9%			-1,012,610	3,613,574	20 Feb 2026	Direct
Frank Torti	ROIV	Common Shares	Sale	-9.25%	$38,388,000	$27.42	-1,400,000	13,736,547	19 Feb 2026	Direct
Frank Torti	ROIV	Common Shares	Options Exercise	10.2%			1,400,000	15,136,547	19 Feb 2026	Direct
Frank Torti	ROIV	Stock Option (Right to Buy)	Options Exercise	-23.2%			-1,400,000	4,626,184	19 Feb 2026	Direct
Eric Venker	ROIV	Common Shares	Sale	-10.8%	$5,298,000	$26.49	-200,000	1,654,597	13 Feb 2026	Direct
Eric Venker	ROIV	Common Shares	Options Exercise	12.1%			200,000	1,854,597	13 Feb 2026	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.